iBio Conference Call Summary Company Overview - **Company**: iBio (NYSEAM:IBIO) - **Event**: FY Conference on February 26, 2026 - **Speakers**: Martin Brenner (CEO and CSO), Felipe Duran (CFO) Industry Insights - **Focus Area**: Obesity treatment and related therapies - **Key Drug Class**: GLP-1 (Glucagon-like peptide-1) drugs have shown significant efficacy in obesity treatment, previously achievable only through invasive surgery [3][4] - **Market Need**: There is a growing need for therapies that address the shortcomings of GLP-1 drugs, particularly in preventing lean mass loss and maintaining weight loss [7][9] Core Strategies and Products - **Portfolio Strategy**: iBio is focusing on second-generation drugs that address unmet patient needs beyond GLP-1s, including: - **IBIO-600**: A myostatin molecule aimed at preventing lean mass loss during weight loss [7] - **Activin E**: A long-acting molecule that targets fat-specific weight loss while preserving muscle [14][19] - **Bispecific Molecule**: Targeting myostatin and activin A for conditions like HFpEF (Heart Failure with preserved Ejection Fraction) and obesity [11][30] Clinical Development and Milestones - **Upcoming Data**: Non-human primate data for IBIO-610 expected in the next 30 to 60 days, with presentations planned at ADA ObesityWeek and the European Diabetic Association meeting [10][40] - **IND Filings**: Plans to file for IND equivalent in Australia by the second half of 2026, with first patient dosing anticipated in early 2027 [10][11] - **Clinical Trials**: Emphasis on Phase 1 studies for IBIO-610, leveraging insights from competitors like Arrowhead and Wave [42][44] Market Potential - **Obesity Statistics**: Approximately 1 billion obese individuals worldwide, with a treatable population estimated at 100 to 200 million [19][20] - **Antibody Modality**: iBio's approach to using antibodies for obesity treatment is expected to allow for scalable production and flexibility in market entry [20] Competitive Landscape - **Differentiation**: iBio aims to differentiate its products from existing therapies by focusing on mechanisms that reduce adverse effects associated with GLP-1s and other treatments [8][32] - **Market Position**: The company is positioned as a potential leader in the obesity treatment space, particularly with its unique antibody approaches [52] Financial Overview - **Market Capitalization**: iBio has a market cap of approximately $500 million, with a low float of 34.5 million shares outstanding [36] - **Funding**: The company is well-capitalized, with cash reserves expected to last until the first quarter of 2028, allowing for continued development of its assets [36] Additional Insights - **Patient Journey**: Highlighted the challenges patients face with GLP-1 treatments, including muscle loss and rapid weight regain after discontinuation [5][6] - **Regulatory Considerations**: Acknowledgment of the lack of a regulatory path for weight maintenance drugs, but optimism that high unmet medical needs will drive future decisions [9] Conclusion - iBio is strategically positioned to address significant unmet needs in obesity treatment through innovative drug development and a focus on maintaining muscle mass during weight loss. The upcoming clinical data and regulatory filings will be critical in establishing its market presence and therapeutic efficacy.

Core Insights - Bristol Myers (BMY) is focusing on its growth portfolio, including drugs like Reblozyl, to drive revenue growth in upcoming quarterly results [1][8] - Reblozyl, co-developed with Merck, has annualized sales exceeding $2 billion and is a significant growth driver for the company [1] Sales Performance - Reblozyl generated sales of $1.66 billion in the first nine months of 2025, reflecting a 35% year-over-year increase [3][8] - The Zacks Consensus Estimate for fourth-quarter Reblozyl sales is $636 million, while the model estimate is $641 million [3] Competitive Landscape - Keros Therapeutics is developing elritercept for transfusion-dependent anemia, which may compete with Reblozyl [5] - Reblozyl also faces competition from established erythropoiesis-stimulating agents (ESAs) like Procrit [6] Financial Outlook - BMY's legacy portfolio is under pressure from generic competition, impacting sales of drugs like Revlimid and Pomalyst [4][8] - The Zacks Consensus Estimate for 2025 EPS has decreased to $6.09 from $6.53 over the past 60 days [11] Valuation Metrics - BMY is trading at a price/earnings ratio of 9.23x forward earnings, which is lower than the large-cap pharma industry's average of 18.42x [10]

Core Insights - Sarepta Therapeutics (SRPT) announced positive three-year top-line data from Part 1 of the phase III EMBARK study, demonstrating that Elevidys effectively slows disease progression in ambulatory individuals with Duchenne muscular dystrophy (DMD) aged 4 to 7 years at the time of dosing [1][2] Group 1: Study Results - The three-year data indicated that Elevidys led to statistically significant and clinically meaningful improvements in patients' ability to control and coordinate movement, with 52 patients maintaining higher motor function as measured by North Star Ambulatory Assessment (NSAA) scores above baseline [2][5] - Elevidys slowed disease progression by 73% as measured by time to rise (TTR) and by 70% as measured by the 10-meter walk run (10MWR) compared to an external control group [6][7] Group 2: Market Response - Following the announcement of the positive data, SRPT shares rose nearly 8% [2] - Over the past year, Sarepta Therapeutics' shares have declined 80.5%, contrasting with the industry's 17.2% rise [2] Group 3: Product Background - Elevidys is the first and only approved gene therapy for treating DMD, having received FDA approval in June 2023 [9] - The therapy was initially suspended for non-ambulatory patients in the U.S. after two deaths were reported, leading to significant label changes and restrictions on its use [10] Group 4: Financial Performance - In Q3 2025, SRPT generated revenues of $131.5 million from Elevidys, a decline from $181 million in the same period of 2024 due to lower volumes following the suspension [11] - The latest three-year data may help improve Elevidys' sales in future quarters, contributing to the recent price increase [11]

Core Insights - Janux Therapeutics (JANX) has entered a strategic collaboration and exclusive global license agreement with Bristol Myers Squibb (BMY) to develop tumor-activated therapies for solid tumors [2][4] - The partnership validates Janux's proprietary tumor-activated immunotherapy platforms and enhances its presence in the oncology sector [2][12] Financial Aspects - Janux is eligible for up to $50 million in upfront and near-term milestone payments, with potential additional milestones totaling approximately $800 million [5][9] - The deal allows Janux to leverage its platform expertise while transferring later-stage development risks to BMY, a large pharmaceutical partner [10] Development and Commercialization - Janux will lead preclinical development until the IND submission, after which BMY will assume responsibility for clinical development and global commercialization [6][10] - Janux will remain involved through the completion of the first phase I study, ensuring continuity in the development process [6] Clinical Pipeline - Janux currently has two tumor-activated T cell engagers in clinical development targeting prostate-specific membrane antigen (PSMA) and epidermal growth factor receptor (EGFR) across various solid tumors [11] - The collaboration with BMY serves as a validation of Janux's tumor-activated approach and enhances the credibility of its broader pipeline strategy [12]

Core Insights - Marker Therapeutics' shares have increased by approximately 114% over the past three months, primarily due to positive momentum surrounding its lead candidate, MT-601, which has enhanced investor confidence [1][7] Clinical Development - The phase I APOLLO study for MT-601 has shown promising results, with about 66% of patients with Non-Hodgkin Lymphoma achieving an objective response and 50% achieving a complete response [2][3] - The responses in the APOLLO study were durable, lasting from three to 24 months, with some patients maintaining benefits beyond six months, including responses extending over one year [2] - MT-601 also demonstrated a 78% response rate in patients with Hodgkin Lymphoma, leading the company to advance to the dose expansion phase for patients with relapsed diffuse large B cell lymphoma [3] Future Prospects - Additional clinical data from the APOLLO study is anticipated in the first half of 2026, which is expected to serve as a significant catalyst for the stock [3] - The company plans to initiate clinical studies for MT-601 targeting pancreatic cancer in the first half of 2026 [6] Financial Position - Marker Therapeutics has secured non-dilutive funding from various institutions, including the National Institutes of Health, to support the development of MT-601 and its Off-the-Shelf (OTS) program [10] - The company raised approximately $10 million through its at-the-market facility, extending its cash runway into 2026 and providing financial stability for ongoing clinical development [11] Manufacturing and Collaboration - Marker Therapeutics has entered into a strategic manufacturing collaboration with Cellipont to enhance the production capabilities of MT-601 [8] Additional Developments - The company has made progress with its OTS platform, having treated its first patient in a phase I RAPID study for MT-401, which was well-tolerated without side effects [9]

Core Insights - Novartis' ianalumab received Breakthrough Therapy designation from the FDA for treating adult patients with Sjogren's disease, a chronic autoimmune disorder [1][6] - Ianalumab is a monoclonal antibody that targets the BAFF receptor to deplete B-cells and inhibit their activation and survival [1] - The Breakthrough Therapy designation is based on positive results from phase III NEPTUNUS-1 and NEPTUNUS-2 studies, which showed significant improvements in disease activity compared to placebo [2][6] Clinical Data - The NEPTUNUS studies demonstrated clinically meaningful reductions in ESSDAI scores, a measure of systemic disease activity in Sjogren's syndrome [2] - Ianalumab exhibited a favorable safety profile, with tolerable side effects reported [3] - If approved, ianalumab would be the first targeted therapy for Sjogren's disease [3] Regulatory and Market Outlook - Novartis plans to submit regulatory applications for ianalumab to global health authorities, including the FDA, starting in early 2026 [3][6] - Over the past year, Novartis shares have increased by 48%, outperforming the industry average rise of 24.1% [3] Pipeline Expansion - Ianalumab is also being investigated for other B-cell-driven autoimmune diseases, including immune thrombocytopenia, systemic lupus erythematosus, and lupus nephritis [8] - Positive results from the phase III VAYHIT2 study indicated that ianalumab combined with eltrombopag extended disease control in ITP patients by 45% [9] - In the VAYHIT2 study, 62% of patients treated with ianalumab achieved sustained platelet response compared to 39% in the placebo group [10]

Core Insights - Axsome Therapeutics (AXSM) has initiated a phase III study named FORWARD to evaluate AXS-14 (esreboxetine) for managing fibromyalgia, marking a significant step in its drug development process [1][8] - AXS-14 is an investigational oral drug aimed at increasing norepinephrine levels in the brain to alleviate chronic pain and related symptoms associated with fibromyalgia [1] Study Details - The FORWARD study is a phase III double-blind, placebo-controlled withdrawal trial involving patients with fibromyalgia, where participants who respond to treatment during a 12-week open-label period will be randomized to either continue AXS-14 at 8 mg once daily or switch to placebo for up to 12 weeks [2] - The primary endpoint of the study is to measure the time from randomization to the loss of therapeutic response [2][8] Market Performance - Over the past year, AXSM's shares have increased by 89.4%, significantly outperforming the industry average rise of 18.7% [3] Regulatory Background - Axsome submitted a new drug application (NDA) for AXS-14 for fibromyalgia in May 2025, which was delayed from an earlier timeline of the first quarter of 2024 [5] - In June 2025, the FDA issued a Refusal to File (RTF) letter regarding the NDA, citing inadequacies in one of the placebo-controlled studies, prompting Axsome to initiate the FORWARD study to address these concerns [6][8] Disease Context - Fibromyalgia is a chronic neurological pain disorder affecting approximately 17 million people in the United States, characterized by widespread pain, fatigue, sleep disturbances, and other symptoms [7]

Core Insights - CG Oncology (CGON) shares have increased nearly 32% in the past week following the announcement of earlier-than-expected top-line data from the phase III PIVOT-006 study, now anticipated in the first half of 2026 [1][8] - Over the last six months, CGON shares have surged 112.8%, significantly outperforming the industry growth of 22.9% [3] Study Details - The phase III PIVOT-006 study is assessing the efficacy of adjuvant intravesical cretostimogene grenadenorepvec against active surveillance in over 360 adult patients with intermediate-risk non-muscle invasive bladder cancer (IR NMIBC) post-tumor resection [2] - The primary endpoint is recurrence-free survival (RFS), with secondary endpoints including RFS at specific intervals and progression-free survival [2] Regulatory and Development Updates - CG Oncology has reported positive durability and response data from the phase III BOND-003 study for high-risk NMIBC patients unresponsive to Bacillus Calmette Guerin, with the FDA granting Fast Track and Breakthrough Therapy designations in December 2023 [6] - A rolling biologics license application submission is underway, expected to be completed in 2026 [6] - A separate phase II CORE-008 study is also evaluating the safety and effectiveness of cretostimogene in high-risk NMIBC [7] Market Context - With no FDA-approved therapies available for IR NMIBC patients post-surgery, the accelerated timeline for the phase III study and positive late-stage data have bolstered expectations for regulatory approval, enhancing investor confidence [9]

Core Insights - TG Therapeutics (TGTX) shares increased nearly 7% in after-hours trading after the release of preliminary fourth-quarter and full-year 2025 results that exceeded expectations [1] - The company provided optimistic guidance for 2026, highlighting key anticipated milestones related to Briumvi label expansion studies and other pipeline candidates [1] Financial Performance - TG Therapeutics expects total global revenues of approximately $616 million for full-year 2025, surpassing the previous guidance of $600 million and the Zacks Consensus Estimate of $604 million [3] - Briumvi U.S. net product revenues are projected to be around $182 million for the fourth quarter of 2025 [3] - For full-year 2025, Briumvi net product sales are expected to be approximately $594 million in the United States, exceeding the November guidance of around $585 million [4] 2026 Outlook & Pipeline Goals - TGTX anticipates 2026 revenues in the range of $875 million to $900 million, including $825 million to $850 million from U.S. Briumvi sales, indicating potential double-digit year-over-year growth compared to expected 2025 figures [7][8] - The company expects operating expenses of around $350 million for the full year 2026 [8] - Key milestones for 2026 include the announcement of pivotal topline data from the ENHANCE study, which aims to consolidate Briumvi infusions, and results from the subcutaneous Briumvi formulation [9][10] - TG Therapeutics is also developing azer-cel, an allogeneic CD19-directed CAR T-cell therapy, with preliminary phase I data expected in the second half of 2026 [11]

Core Viewpoint - Shares of Travere Therapeutics (TVTX) declined by 14.6% following the FDA's announcement to extend the review timeline for the supplemental new drug application (sNDA) for Filspari in the FSGS indication by three months, with a new decision date set for April 13, 2026 [1][7]. FDA Review Extension - The FDA extended the review timeline after Travere submitted additional information to better define the clinical benefit of Filspari, classifying these submissions as a major amendment to the sNDA [2]. - No new safety or manufacturing data was requested by the FDA for Filspari [2]. Product Information - Filspari is currently approved to slow kidney function decline in adults with primary IgA nephropathy at risk of disease progression [3]. - FSGS is a rare kidney disorder affecting over 40,000 patients in the U.S. and a similar number in the EU, characterized by progressive kidney scarring and proteinuria [5][8]. - If approved for FSGS, Filspari would be the first FDA-approved therapy for this condition, addressing podocyte injury, a critical factor in FSGS progression [8]. Market Performance - Over the past six months, Travere Therapeutics' shares have increased by 72.1%, outperforming the industry average increase of 20.4% [4]. Financial Projections - Preliminary sales for Q4 2025 are expected to be around $127 million, with full-year 2025 net product sales projected at approximately $410 million in the U.S. [10]. - Preliminary U.S. net product sales of Filspari for Q4 2025 are estimated at $103 million, reflecting a 108% year-over-year increase, with full-year sales around $322 million [11]. Partnerships and Future Plans - In October 2025, Travere received a $40 million milestone payment from CSL Vifor after achieving market access milestones, with further payments expected tied to additional market access and sales [12]. - The company plans to continue building clinical evidence to support Filspari as a foundational treatment for IgAN through ongoing clinical studies, with the potential label expansion for FSGS likely to boost sales in 2026 [13].